Adaptive Phage Therapeutics, Inc., a Gaithersburg, MD-based clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, raised $20m in further funding.
The AMR Action Fund has joined an existing $41m Series B round as a co-investor. The round was initiated in May 2021 and led by Deerfield Management Company, with participation from a second institutional investor and Mayo Clinic. Martin Heidecker, PhD, Chief Investment Officer of the AMR Action Fund, will join APT’s Board of Directors.
Image: https://www.finsmes.com
{iframe}https://www.finsmes.com/2022/04/adaptive-phage-therapeutics-raises-further-20m-extends-series-b-to-61m.html{/iframe}